Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Estrogen Guidance Recommends Labeling Changes On Dementia Risk

Executive Summary

FDA is recommending hormone replacement therapy class labeling changes to include new dementia risk information on estrogen-alone therapy in a 1draft guidance on noncontraceptive estrogen drug products

You may also be interested in...

Estrogen Products Guidance To Be Revised; FDA Will Outline Plans In June

FDA will make significant changes to a 2003 FDL-1draft guidance on estrogen products and reissue a new draft

Hormone Therapy Dementia “Black Box” Warning Sought By FDA

FDA is recommending a hormone replacement therapy class "black box" warning on an increased risk of dementia with use of estrogen and combination estrogen/progestin products

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts